Paricalcitol Injection Long-term Safety Study
Phase 2
- Conditions
- Secondary Hyperparathyroidism
- Registration Number
- JPRN-jRCT2080220578
- Lead Sponsor
- Abbott Japan Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Aged 20 or over
Subjects allocated to paricalcitol groups in the phase IIb study (dose-response study) and completed it with good tolerability to paricalcitol injection
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of subjects with iPTH measurement =<180 pg/mL at the final visit, etc.
- Secondary Outcome Measures
Name Time Method